Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Cisplatin|DRUG: Paclitaxel
Sponsor: Dana-Farber Cancer Institute
Collaborators: Myriad Genetics, Inc.|Translational Breast Cancer Research Consortium